Prolia (Denosumab) Legal & Patent Challenges: What Women Need to Know

When Was Prolia FDA-Approved and What Is It Approved For?

Prolia received FDA approval on June 1, 2010 for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The approval was based primarily on the FREEDOM trial, a phase 3 randomized controlled study of 7,868 women aged 60 to 90. Since that initial approval, the FDA has expanded Prolia's indications to include bone loss in women receiving aromatase inhibitor therapy for breast cancer, bone loss in men with osteoporosis, and bone loss in patients on glucocorticoid therapy.

For women, this means denosumab sits at the center of several conditions that disproportionately affect female biology: postmenopausal bone loss, aromatase inhibitor-induced osteoporosis in breast cancer survivors, and glucocorticoid-induced bone loss in women managing autoimmune conditions at higher rates than men.

The FREEDOM Trial: The Data Behind the Approval

The FREEDOM trial published in the New England Journal of Medicine in 2009 enrolled only postmenopausal women, which means the efficacy data is actually more directly applicable to your biology than is the case for many drugs studied in mixed-sex populations. Over 36 months, denosumab 60 mg every 6 months reduced new vertebral fractures by 68% compared with placebo, reduced hip fractures by 40%, and reduced nonvertebral fractures by 20%.

The women enrolled had a mean age of 72 years and a mean lumbar spine T-score of approximately -2.8, placing them solidly in the osteoporosis range. The trial did not include premenopausal women or women in early perimenopause, which matters for understanding the limits of the evidence base.

Expanded Approvals Relevant to Women

The aromatase inhibitor-associated bone loss indication is particularly relevant. Aromatase inhibitors such as anastrozole, letrozole, and exemestane suppress estrogen to near-undetectable levels, accelerating bone turnover in postmenopausal breast cancer survivors at a rate that can mirror early menopause bone loss compressed into a shorter window. Women on these therapies lose bone at roughly 2 to 3 times the rate of untreated postmenopausal women in the first year of therapy.

What Does the Current Prolia FDA Label Say?

The Prolia prescribing information carries several warnings that women need to understand plainly.

Hypocalcemia: The Most Immediate Serious Risk

Denosumab can cause severe, symptomatic, and potentially fatal hypocalcemia. The label requires that calcium and vitamin D levels be adequate before every dose. Women with chronic kidney disease, particularly stage 4 or 5, are at the greatest risk. If you have renal impairment, your clinician should check a serum calcium level before each injection and supplement accordingly.

The label specifies that patients should receive at least 1,000 mg of calcium and 400 IU of vitamin D daily unless hypercalcemia is present. Many women, particularly in perimenopause and postmenopause, are already calcium-deficient, which makes this a real clinical concern rather than a theoretical one.

Osteonecrosis of the Jaw

Osteonecrosis of the jaw (ONJ) has been reported with denosumab. The risk is substantially higher with the oncologic dose (Xgeva 120 mg monthly) than with the osteoporosis dose (Prolia 60 mg every 6 months), but it exists with Prolia. Dental procedures that involve bone manipulation, such as tooth extractions or implants, should be completed before starting denosumab if possible. Discuss your dental health with your prescribing clinician before your first dose.

Atypical Femoral Fractures

Like bisphosphonates, long-term denosumab use is associated with atypical subtrochanteric and diaphyseal femoral fractures. These fractures are rare but tend to occur with minimal trauma and often present with prodromal thigh or groin pain weeks to months before the fracture occurs. If you develop new thigh pain during denosumab therapy, that warrants imaging before dismissing it as a muscle strain.

Rebound Bone Loss After Discontinuation

The label includes a specific warning about rapid bone loss and increased fracture risk upon discontinuation. This is a feature of denosumab that differs fundamentally from bisphosphonates, which bind to bone mineral and have a long residual effect after stopping. Denosumab's RANK-L inhibition reverses within months of the last dose, causing a rebound in bone turnover markers and vertebral fracture risk that can exceed baseline. A 2017 analysis of FREEDOM extension data found multiple vertebral fractures occurring in some patients within 12 to 24 months of stopping denosumab without follow-on antiresorptive therapy. If you stop Prolia for any reason, your clinician should transition you to a bisphosphonate.

Pregnancy, Lactation, and Contraception: What the Data Actually Shows

Denosumab is contraindicated in pregnancy. Period.

Pregnancy: Fetal Risk Is Real

Animal studies show that denosumab causes fetal harm. In cynomolgus monkeys given doses equivalent to human exposure levels, denosumab resulted in absent peripheral lymph nodes, abnormal bone development, and increased rates of stillbirth and postnatal death. RANK-L signaling is essential for fetal bone development and immune system formation. Blocking it pharmacologically during gestation carries a plausible and serious mechanism for harm.

There are no adequate human studies in pregnant women, and none are expected given the animal signal. The drug is classified as causing fetal harm based on animal reproductive toxicity data. The FDA label states that Prolia should not be used during pregnancy, and women of reproductive potential should use effective contraception during therapy and for at least 5 months after the last dose. The 5-month window reflects denosumab's approximate half-life of 25 to 28 days and the time required for serum concentrations to fall to negligible levels.

Who Gets Prescribed This During Reproductive Years?

Premenopausal women with osteoporosis do sometimes receive denosumab, particularly those with cancer treatment-related bone loss, glucocorticoid-induced osteoporosis, or severe primary osteoporosis. In these cases, reliable contraception is not optional. An unintended pregnancy on denosumab is a serious situation requiring immediate referral to maternal-fetal medicine.

If you are in your reproductive years and your clinician is considering denosumab, ask explicitly: "What contraception is required, and for how long after my last injection?" The answer is highly effective contraception throughout treatment and for 5 months after the final dose.

Lactation

It is not known whether denosumab is present in human milk. Given the potential for serious adverse effects on a nursing infant's bone development and immune function, the label recommends against breastfeeding during treatment and for 5 months after the last dose. This is a meaningful consideration for postpartum women who may have pregnancy-associated osteoporosis, a rare but real condition.

Patent Portfolio and Legal Challenges: The Biosimilar Delay

Prolia's path to biosimilar competition has been slower than many anticipated, and understanding why matters because biosimilar availability directly affects what you pay.

Amgen's Patent Strategy

Amgen holds multiple patents listed in the FDA Orange Book for Prolia, covering the denosumab molecule itself, formulation aspects, and methods of use. Amgen pursued an aggressive patent lifecycle strategy similar to the approach it used for Enbrel (etanercept). Competitors seeking to market biosimilar denosumab in the US were required to manage the Biologics Price Competition and Innovation Act (BPCIA) "patent dance" process, which involves sharing manufacturing and clinical data and engaging in formal patent dispute resolution.

Paragraph IV Certifications and Litigation

Several biosimilar applicants filed Paragraph IV certifications asserting that Amgen's listed patents were invalid, unenforceable, or would not be infringed by their biosimilar products. The FDA's Paragraph IV certification database reflects multiple denosumab biosimilar applications that triggered 30-month litigation stays, effectively delaying market entry while patent disputes proceeded through federal court.

The legal disputes centered on claims about:

• Formulation patents covering the stabilized liquid formulation at specific pH ranges
• Method-of-use patents covering dosing intervals and combination use with calcium/vitamin D
• Manufacturing process patents covering antibody production methods

These are standard levers in biologic patent litigation, but the combination created a thicket that extended Amgen's effective market exclusivity well beyond the initial 12-year BPCIA exclusivity period.

The First Biosimilar Approval

The FDA approved the first US denosumab biosimilars in September 2024: Jubbonti (denosumab-bbdz, Samsung Bioepis/Organon) for the Prolia indications, and Wyost for the Xgeva indications. This approval followed extensive patent litigation and settlement agreements between Amgen and Samsung Bioepis that included a negotiated market entry date.

The approval means that, for the first time, prescribers and insurers have a substitutable option. The FDA designated these products as interchangeable biosimilars, meaning pharmacists in states that allow biosimilar substitution may dispense them without a new prescription specifying the reference product.

What This Means for Your Out-of-Pocket Cost

Prolia list price has historically run approximately $1,300 to $1,400 per injection, or roughly $2,600 to $2,800 per year. Biosimilar entry typically drives 15 to 35% price reductions for brand biologic products in the short term, with steeper reductions as additional biosimilars enter the market. If you are currently paying out of pocket or have high cost-sharing, ask your pharmacy or insurer whether the biosimilar is now available on formulary. The FDA's biosimilar product information page is updated as new products receive approval.

EMA Approval and European Regulatory History

The European Medicines Agency approved denosumab (Prolia) in May 2010, one month before the FDA, based on the same FREEDOM trial data. The EMA's European Public Assessment Report (EPAR) includes post-marketing pharmacovigilance data from the EU that supplements the US post-market surveillance dataset.

European biosimilar approvals preceded the US by several years due to differences in regulatory timelines and patent enforcement mechanisms. By 2022, multiple denosumab biosimilars were available in European markets, providing real-world comparative safety and effectiveness data that informed US biosimilar development and regulatory review.

Who Is Prolia Right For, and Who Should Be Cautious?

The following framework is based on WomanRx clinical editorial review and synthesizes current guideline recommendations from The Menopause Society, ACOG, and published fracture risk tools.

Strong Candidates (Postmenopause)

• Women aged 65 and older with a T-score of -2.5 or lower at the lumbar spine, total hip, or femoral neck
• Women aged 50 to 64 with a 10-year major osteoporotic fracture probability at or above 20% or hip fracture probability at or above 3% by FRAX calculation
• Women who have had a prior fragility fracture regardless of BMD
• Women who cannot tolerate or have contraindications to oral bisphosphonates (significant esophageal disease, inability to remain upright 30 to 60 minutes, chronic kidney disease where bisphosphonate use is limited)
• Women on aromatase inhibitor therapy with documented bone loss

The Menopause Society 2023 position statement on osteoporosis management identifies denosumab as a first-line option for postmenopausal women at high fracture risk, particularly those with renal insufficiency where bisphosphonate use is complicated.

Women Who Need Extra Caution

• Women with hypocalcemia or vitamin D deficiency that has not been corrected before the first dose
• Women with chronic kidney disease stage 4 or 5 (hypocalcemia risk is markedly elevated)
• Women planning dental surgery within the next 6 months
• Women of reproductive age without reliable contraception
• Women who are unreliable for follow-up injections every 6 months (missed doses increase rebound fracture risk)

Perimenopause and Early Postmenopause

Most guidelines do not recommend initiating denosumab in perimenopausal women or women in early postmenopause without significant fracture risk, because the rebound discontinuation risk and the requirement for indefinite or transitioned therapy represent a long management commitment. Bisphosphonates, which have a built-in "drug holiday" option after 5 years of treatment, are generally preferred as first-line agents for women in their early 50s.

ACOG Practice Bulletin No. 129 acknowledges denosumab as an effective second-line option for postmenopausal women who have not responded adequately to bisphosphonates or cannot use them.

Post-Market Safety Surveillance: What Has Emerged Since 2010?

The FDA's Sentinel System, a national electronic surveillance network using real-world claims and electronic health record data, has contributed to ongoing denosumab safety monitoring since approval.

Post-approval signals that have strengthened or emerged include:

• Atypical femoral fractures with long-term use (>3 years), prompting a label update
• Severe hypocalcemia occurring more frequently than trial data suggested, particularly in women with undiagnosed renal impairment or low dietary calcium intake
• Multiple vertebral fractures after discontinuation, leading to the 2017 label update adding the rebound warning
• Skin infections (cellulitis) occurring at slightly higher rates in Prolia-treated patients than in bisphosphonate-treated comparators in observational data

A 2020 FDA Drug Safety Communication reinforced the hypocalcemia risk and noted that cases requiring hospitalization had been reported in women who appeared clinically stable at the time of injection.

The Cardiovascular Signal That Did Not Materialize

One concern raised in early post-market discussion was whether RANK-L inhibition in vascular tissue might affect cardiovascular risk, given RANK-L's presence in arterial calcification pathways. A pre-specified cardiovascular analysis of the FREEDOM extension study did not find a significant increase in cardiovascular events with denosumab over 10 years of follow-up, which is reassuring for postmenopausal women who already carry elevated baseline cardiovascular risk.

The Evidence Gap: What We Do Not Know About Women Across Life Stages

Women have been the primary population studied with Prolia, which is somewhat unusual in drug development and reflects the sex-specific nature of the primary indication. However, the data has important gaps:

• Premenopausal women: No large randomized trial data exists. Use in premenopausal women is off-label for most indications, and the FREEDOM trial enrolled only postmenopausal women aged 60 to 90.
• Perimenopause: No dedicated trial data. Effects of fluctuating estrogen on denosumab response during the menopause transition have not been prospectively studied.
• Women with PCOS: Women with PCOS who have oligo- or amenorrhea may have reduced bone density, but denosumab has not been studied specifically in this population.
• Women with premature ovarian insufficiency (POI): POI causes accelerated bone loss beginning before age 40. The data on denosumab in POI is limited to case reports and small series.
• Race and ethnicity: The FREEDOM trial was approximately 80% white. Fracture risk epidemiology differs by race and ethnicity, and BMD thresholds for clinical decision-making may not translate equally across all groups.

These are real gaps. When your clinician recommends denosumab, ask whether the recommendation is based on data from women who resemble you in terms of age, menopausal status, and health history.

Denosumab and Conditions Beyond Osteoporosis: What Women Ask About

Breast Cancer Bone Metastases (Xgeva)

A different formulation of denosumab, Xgeva at 120 mg monthly, is FDA-approved for prevention of skeletal-related events in women with bone metastases from solid tumors including breast cancer. This is a distinct product with a different dose, indication, and risk profile. Xgeva carries a substantially higher ONJ risk than Prolia. A 2011 trial comparing denosumab versus zoledronic acid in breast cancer bone metastases found denosumab superior in delaying skeletal-related events.

Endometriosis and Bone Loss

Women with endometriosis treated with GnRH agonists such as leuprolide experience significant bone loss from medically induced hypoestrogenemia. GnRH agonist therapy for 6 months can reduce lumbar spine BMD by 3 to 6%. Denosumab has been studied in small trials in this context, but the standard of care for GnRH agonist-induced bone loss remains add-back estrogen therapy rather than denosumab.

Giant Cell Tumor of Bone

Denosumab is FDA-approved (as Xgeva) for adults and skeletally mature adolescents with unresectable giant cell tumor of bone. This indication affects younger women and sometimes requires careful management in women of reproductive age given the contraception requirements discussed above.